Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 10:35:45 2024-05-29 pm EDT			5-day change	1st Jan Change
1.69 ^HKD	0.00%		-10.11%	-53.31%

May. 22	Jacobio Pharmaceuticals Group's Lung Cancer Drug Get NDA from China's NMPA	MT
May. 21	Jacobio Pharmaceuticals Group Co., Ltd. Announces New Drug Application for Its Independently Developed Novel KRAS G12C Inhibitor Glecirasib (Jab-21822)	CI

Jacobio Pharmaceuticals Group Co., Ltd. Announces Company Secretary Changes

March 26, 2021 at 10:49 am EDT

Jacobio Pharmaceuticals Group Co., Ltd. announced that Ms. Ching Man Yeung has tendered resignation as the joint company secretary and an authorized representative of the Company. The company announced that Mr. Lok Kwan Yim has been appointed as a Joint Company Secretary and the Authorised Representatives effective March 26, 2021.

Latest news about Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group's Lung Cancer Drug Get NDA from China's NMPA	May. 21	MT
Jacobio Pharmaceuticals Group Co., Ltd. Announces New Drug Application for Its Independently Developed Novel KRAS G12C Inhibitor Glecirasib (Jab-21822)	May. 21	CI
Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab	May. 13	MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer	May. 10	CI
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%	May. 06	MT
Jacobio Pharma Announces Its KRAS G12C Inhibitor Reached the Primary Endpoint	Apr. 30	CI
Jacobio Pharmaceuticals Plans Auditor Change	Apr. 25	MT
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention	Apr. 09	MT
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting	Apr. 09	CI
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses	Apr. 01	MT
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Jacobio Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Clinical Trial for Anti-Tumor Drug; Shares Surge 16%	Mar. 01	MT
Jacobio Pharmaceuticals Group Co., Ltd. Receives US FDA Investigational New Drug Clearance for P53 Y220C Activator JAB-30300	Feb. 29	CI
Hong Kong Stocks Fall as Chinese Central Bank Leaves Key Policy Rate on Hold; Jacobio Falls 11% Despite Drug Progress	Feb. 19	MT
China Approves Jacobio's Phase 3 Trial of Non-Small Cell Lung Cancer Drug; Shares Plummet 13%	Feb. 19	MT
Jacobio Pharma Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor	Feb. 18	CI
Jacobio Presents Clinical Data on Pancreatic Cancer Treatment at Oncology Meet; Shares Fall 7%	Jan. 22	MT
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors At the 2024 ASCO GI	Jan. 19	CI
Jacobio to Present Clinical Results of Pancreatic Cancer Drug in US Meet; Shares Jump 3%	Dec. 07	MT
Jacobio Pharmaceuticals Group Co., Ltd. Announces Clinical Results in the Oral Abstract Session of Clinical Oncology Gastrointestinal Cancers Symposium	Dec. 06	CI
Jacobio Presents Clinical Data on Anti-Tumor Drug at Oncology Congress	23-10-23	MT
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with Jab-3312 At Esmo	23-10-22	CI
Jacobio Pharmaceuticals Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
China Grants Breakthrough Therapy Status to Jacobio's Pancreatic Cancer Treatment; Shares Rise 5%	23-08-08	MT
Jacobio Pharmaceuticals Group Co., Ltd.'S In-House KRAS G12C Inhibitor Jab-21822 Granted Breakthrough Therapy Designation for Pancreatic Cancer Patients	23-08-07	CI

Chart Jacobio Pharmaceuticals Group Co., Ltd.

Duration

Period

Chart Jacobio Pharmaceuticals Group Co., Ltd.

More charts

Company Profile

Jacobio Pharmaceuticals Group Co Ltd is a China-based investment holding company mainly engaged in the research and development of new drugs at the clinical stage. The Company is primarily responsible for the independent discovery and development of innovative tumor therapies. The Company's main drug development projects include JAB-3068 and JAB-3312 clinical stage allosteric SHP2 inhibitors. The Company mainly conducts business within the domestic market.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.568 CNY

Average target price

3.954 CNY

Spread / Average Target

+152.17%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
JACOBIO PHARMACEUTICALS GROUP CO., LTD.	-53.31%	182M
VERTEX PHARMACEUTICALS INCORPORATED	+8.38%	115B
REGENERON PHARMACEUTICALS, INC.	+10.13%	105B
BIONTECH SE	-11.69%	22.71B
ARGENX SE	+2.21%	21.83B
GENMAB A/S	-10.88%	18.18B
WUXI APPTEC CO., LTD.	-41.90%	16.52B
BEIGENE, LTD.	-16.00%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+2.28%	14.14B
SAREPTA THERAPEUTICS, INC.	+20.54%	10.71B

Bio Therapeutic Drugs